| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (replaced TA295) |
|
Medicine details |
|
| Medicine name | everolimus (Afinitor®) |
| Formulation | tablet |
| Reference number | 1384 |
| Indication | Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/09/2012 |
| NICE guidance | |